VCP
IHE icon

Verus Capital Partners’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Verus Capital Partners’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$34K Sell
753
-6
-0.8% -$303 0.01% 611
2019
Q4 		$41K Buy
+759
New +$37.4K 0.01% 663

Other funds holding IHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Verus Capital Partners's IHE Position: Q1 2020 in Review

Verus Capital Partners reduced its iShares US Pharmaceuticals ETF (IHE) stake by 0.79% in Q1 2020, selling an estimated $303 and leaving 753 shares worth $34K. The position accounts for 0.01% of the portfolio, ranked #611.

Verus Capital Partners first reported a position in IHE in Q4 2019 and has held it in 2 quarters since. The position peaked at $41K in Q4 2019. 92 funds tracked by Wall St. Rank hold IHE as of Q1 2020.

  • Verus Capital Partners held 753 shares of iShares US Pharmaceuticals ETF worth $34K as of Q1 2020.
  • Verus Capital Partners sold 6 iShares US Pharmaceuticals ETF shares in Q1 2020, an estimated $303.
  • iShares US Pharmaceuticals ETF made up 0.01% of Verus Capital Partners's portfolio in Q1 2020, its #611 holding.
  • Verus Capital Partners first reported a position in iShares US Pharmaceuticals ETF in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's iShares US Pharmaceuticals ETF position peaked at $41K in Q4 2019.
  • 92 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.